Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Nov 3:2019:1512326.
doi: 10.1155/2019/1512326. eCollection 2019.

miR-200a Attenuated Doxorubicin-Induced Cardiotoxicity through Upregulation of Nrf2 in Mice

Xiaoping Hu  1 , Huagang Liu  2 , Zhiwei Wang  1 , Zhipeng Hu  1 , Luocheng Li  1
Affiliations

miR-200a Attenuated Doxorubicin-Induced Cardiotoxicity through Upregulation of Nrf2 in Mice

Xiaoping Hu et al. Oxid Med Cell Longev. .

Abstract

Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) was closely involved in doxorubicin- (DOX-) induced cardiotoxicity. MicroRNA-200a (miR-200a) could target Keap1 mRNA and promote degradation of Keap1 mRNA, resulting in Nrf2 activation. However, the role of miR-200a in DOX-related cardiotoxicity remained unclear. Our study is aimed at investigating the effect of miR-200a on DOX-induced cardiotoxicity in mice. For cardiotropic expression, male mice received an injection of an adeno-associated virus 9 (AAV9) system carrying miR-200a or miR-scramble. Four weeks later, mice received a single intraperitoneal injection of DOX at 15 mg/kg. In our study, we found that miR-200a mRNA was the only microRNA that was significantly decreased in DOX-treated mice and H9c2 cells. miR-200a supplementation blocked whole-body wasting and heart atrophy caused by acute DOX injection, decreased the levels of cardiac troponin I and the N-terminal probrain natriuretic peptide, and improved cardiac and adult cardiomyocyte contractile function. Moreover, miR-200a reduced oxidative stress and cardiac apoptosis without affecting matrix metalloproteinase and inflammatory factors in mice with acute DOX injection. miR-200a also attenuated DOX-induced oxidative injury and cell loss in vitro. As expected, we found that miR-200a activated Nrf2 and Nrf2 deficiency abolished the protection provided by miR-200a supplementation in mice. miR-200a also provided cardiac benefits in a chronic model of DOX-induced cardiotoxicity. In conclusion, miR-200a protected against DOX-induced cardiotoxicity via activation of the Nrf2 signaling pathway. Our data suggest that miR-200a may represent a new cardioprotective strategy against DOX-induced cardiotoxicity.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
miR-200a was decreased in DOX-induced cardiac injury: (a) the levels of miRNAs in the hearts (n = 6); (b) the levels of miRNAs in the H9c2 cells (n = 6); (c, d) the levels of miR-200a in the H9c2 cells (n = 6). ∗P < 0.05 compared with the group with saline or PBS.
Figure 2
Figure 2
miR-200a overexpression improved cardiac function in mice: (a) schedule of the acute DOX regime experiment; (b) the levels of miR-200a in the hearts (n = 6); (c) the alteration in body weight (n = 12); (d) alterations in the ratio of heart weight to tibial length (n = 12); (e, f) the level of cTnI and NT-proBNP (n = 6), (g, h) the alteration in +dP/dt and EF in mice (n = 10); (i) cardiac output in the mice (n = 10). ∗P < 0.05 compared with the group with saline. #P < 0.05 compared with mice after DOX injection.
Figure 3
Figure 3
miR-200a improved adult cardiomyocyte contractile properties: (a) the levels of miR-200a; (b) resting cell length; (c) peak shortening; (d, e) maximal velocity of shortening (+dL/dt) and maximal velocity of relengthening (-dL/dt). ∗P < 0.05 compared with the group with saline. #P < 0.05 compared with mice after DOX injection. n = 50 cells from 4 mice per group.
Figure 4
Figure 4
miR-200a reduced oxidative stress in DOX-treated mice: (a) the level of MMP2 and MMP9 in the hearts (n = 6); (b) the level of TNF-α and IL-6 in the hearts (n = 6); (c, d) the levels of GSH and cardiac MDA in the hearts (n = 6); (e) the level of 4-HNE in the hearts (n = 6); (f) the level of SOD2 mRNA in the hearts (n = 6); (g) protein expression of Nrf2 and HO-1 (n = 6). ∗P < 0.05 compared with the group with saline. #P < 0.05 compared with mice after DOX injection.
Figure 5
Figure 5
miR-200a suppressed cardiac apoptosis in DOX-treated mice. (a) TUNEL staining (n = 6). (b) Western analysis indicated the expression of Bax and Bad in the hearts (n = 6). ∗P < 0.05 compared with the group with saline. #P < 0.05 compared with mice after DOX injection.
Figure 6
Figure 6
miR-200a provided cardioprotection via activating the Nrf2 signaling pathway: (a, b) the level of Keap1 and Nrf2 in the H9c2 cells (n = 6); (c) the protein expression of Nrf2 (n = 6); (d) DCF-DA staining; (e, f) the levels of 4-HNE and GSH in the cells (n = 6); (g) the level of Nrf2 in the cells (n = 6); (h) cell viability (n = 6); (i) caspase 3 activity (n = 6). ∗P < 0.05.
Figure 7
Figure 7
miR-200a could not provide cardiac protection against DOX-induced acute cardiotoxicity in Nrf2-deficient mice: (a) schedule of Nrf2 deficiency in mice with the acute DOX treatment; (b) the level of Nrf2 in the hearts (n = 6); (c) EF (n = 8); (d, e) the levels of NT-proBNP and MDA in the hearts (n = 6); (f) caspase 3 activity (n = 6). ∗P < 0.05.
Figure 8
Figure 8
miR-200a protected the hearts from DOX-induced chronic cardiotoxicity: (a) schedule of the acute DOX regime experiment; (b) the level of miR-200a in the hearts (n = 6); (c) survival rate in the groups (n = 15); (d) EF in the four groups (n = 10); (e) the level of 4-HNE in the hearts (n = 6); (f) caspase 3 activity (n = 6). ∗P < 0.05 compared with the group with saline. #P < 0.05 compared with mice after DOX injection.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Octavia Y., Tocchetti C. G., Gabrielson K. L., Janssens S., Crijns H. J., Moens A. L. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. Journal of Molecular and Cellular Cardiology. 2012;52(6):1213–1225. doi: 10.1016/j.yjmcc.2012.03.006. - DOI - PubMed
    1. Eschenhagen T., Force T., Ewer M. S., et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure. 2011;13(1):1–10. doi: 10.1093/eurjhf/hfq213. - DOI - PubMed
    1. Ghigo A., Li M., Hirsch E. New signal transduction paradigms in anthracycline-induced cardiotoxicity. Biochimica et Biophysica Acta. 2016;1863(7):1916–1925. doi: 10.1016/j.bbamcr.2016.01.021. - DOI - PubMed
    1. Maksimenko A. V., Vavaev A. V. Antioxidant enzymes as potential targets in cardioprotection and treatment of cardiovascular diseases. Enzyme antioxidants: the next stage of pharmacological counterwork to the oxidative stress. Heart International. 2012;7(1):p. hi.2012.e3. doi: 10.4081/hi.2012.e3. - DOI - PMC - PubMed
    1. Chaiswing L., Cole M. P., St Clair D. K., Ittarat W., Szweda L. I., Oberley T. D. Oxidative damage precedes nitrative damage in Adriamycin-induced cardiac mitochondrial injury. Toxicologic Pathology. 2004;32(5):536–547. doi: 10.1080/01926230490502601. - DOI - PubMed